IL1B and synovitis: According to the results of this trial, IL-1 inhibition was not an effective analgesic/antiinflammatory treatment in most patients with knee OA and associated synovitis, based on the limited improvement in WOMAC pain scores and lack of synovitis improvement with lutikizumab.